252870-53-4

Basic information

• Product Name: ispronicline
• Synonyms: ispronicline;Ispronicline, (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-Methylpent-4-en-2-aMine;Ispronicline(TC-1734, AZD-3480);(2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-Methylpent-4-en-2-aMine;(E,2S)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
• CAS NO: 252870-53-4
• Molecular Formula: C₁₄H₂₂N₂O
• Molecular Weight: 234.341
• Mol File: 252870-53-4.mol

Chemical Properties

• Boiling Point: bp0.5 90-100°
• Appearance: /
• Density: 0.977±0.06 g/cm3(Predicted)
• PKA: 10.03±0.10(Predicted)
• CAS DataBase Reference: ispronicline(CAS DataBase Reference)
• NIST Chemistry Reference: ispronicline(252870-53-4)
• EPA Substance Registry System: ispronicline(252870-53-4)

Safety Data

• Hazardous Substances Data: 252870-53-4(Hazardous Substances Data)

Usage

Uses

Treatment of cognitive and memory disorders (neuronal nicotinic receptor partial agonist).

Upstream product

• 252870-91-0 (2R)-(4E)-5-(5-isopropoxy-pyridin-3-yl)-4-penten-2-ol 
• 98-59-9 p-toluenesulfonyl chloride 
• 64-17-5 ethanol 
• 312728-34-0 (2S)-(4E)-N-methyl-N-(tert-butoxycarbonyl)-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine 
• 634902-49-1 toluenesulfonic acid (R)-1-methyl-but-3-enyl ester 
• 833453-00-2 (S)-N-methyl-4-penten-2-amine 
• 833453-02-4 (S)-N-tert-butoxycarbonyl-N-methyl-4-penten-2-amine 

Downstream Products

• 957107-03-8 R-mandelic acid salt of (2S)-(4E)-N-methyl-5-[5-isopropoxypyridin-3-yl]-4-penten-2-amine 

Relevant articles and documents

NEW PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OLEFINIC AMINES

An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N- methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.

HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The forma

Compounds capable of activating cholinergic receptors

The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

Compounds capable of activating cholinergic receptors

The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

Pharmaceutical compositions and methods for use

Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine, (4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(5-hydroxypyridin)yl)-4-penten-2-amine.

Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

A pharmaceutical composition incorporates a pharmaceutically effective amount of at least two components, one of those components being a nicotinic compound capable of interacting with nicotinic cholinergic receptors (e.g., a nicotinic agonist, such as E-